Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.58 |
| ▸ | HRH1 | P35367 | 14/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13293801 | 0.93 | HRH1 (0.49) | HTR6HRH1HDAC1HDAC6BAZ2B | |
| SCHEMBL12819819 | 0.92 | HTR6 (0.48) | HTR6HRH1HDAC1HDAC6BAZ2B | |
| SCHEMBL12480415 | 0.89 | HTR6 (0.57) | HTR6HRH1HDAC1HDAC6 | |
| SCHEMBL169904 | 0.89 | HTR6 (0.66) | HTR6HRH1 | |
| SCHEMBL168313 | 0.89 | HTR6 (0.58) | HTR6HRH1HDAC1HDAC6 | |
| SCHEMBL166839 | 0.88 | HTR6 (0.53) | HTR6HRH1HDAC1HDAC6BAZ2B | |
| SCHEMBL168870 | 0.85 | HTR6 (0.63) | HTR6HRH1HDAC1HDAC6 | |
| SCHEMBL169674 | 0.85 | HTR6 (0.54) | HTR6HRH1HDAC1HDAC6 | |
| SCHEMBL166223 | 0.84 | HTR6 (0.52) | HTR6HRH1HDAC1HDAC6BAZ2B | |
| SCHEMBL169431 | 0.83 | HTR6 (0.51) | HTR6HRH1HDAC1HDAC6BAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424366-B1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2016-02-17 | — | — | EP | claimed |
| US-8927571-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-01-06 | — | — | US | claimed |
| US-8741919-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-03 | — | — | US | claimed |
| US-20130190331-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | claimed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | claimed |
| EP-2424366-A1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2011019417-A1 | PYRIDO [4, 3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-02-17 | — | — | WO | claimed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2424366-B1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2424366-B1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | disclosed |
| WO-2011019417-A1 | PYRIDO [4, 3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | HTR6 10/4885HRH1 41/4885HDAC1 4018/4885 |
| US-20130190331-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | HTR6 10/4885HRH1 41/4885HDAC1 4018/4885 |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HTR6 47/4885HRH1 93/4885HDAC1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.